Real World Evidence Centre
The Section of Clinical Medicine and Ageing is working with global healthcare leader Eli Lilly and Company to study the effects of treatment on people with type 2 diabetes, which affects about 95 per cent of those with the disease.
Using routine data gathered from patients undergoing diabetes treatments, the partnership will focus on answering commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis.
The collaboration will initially focus on three key areas: adherence to therapy, triggers for the initiation of injectable therapy, and understanding the perspectives of both the patient and healthcare professional.
Diabetes remains one of society’s most prevalent diseases. More than 387 million people worldwide have type 1 and type 2 diabetes.1 Type 2 diabetes is the most common, accounting for an estimated 90 to 95 per cent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin.
Infection risk in elderly people with reduced glycaemic control – Lancet Diabetes Endocrinol 2016
Lilly enters diabetes research collaboration with Surrey University by PBR Staff Writer - Pharma Business Review
Eli Lilly , Uni of Surrey are pharma partners for diabetes treatment - Current Partnering
Lilly/Surrey Uni form diabetes research pact by Selina McKee - Pharma Times